PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

Surgery for urologic cancers after SARS-CoV-2 infection: Adverse outcomes and optimal delay. Neoadjuvant chemotherapy (NAC) versus adjuvant chemotherapy (AC) in patients with clinically node-positive ...

Contemporary analysis of ureteroenteric strictures after open and robot-assisted radical cystectomy: A population-based study. Prophylactic cranial irradiation (PCI) significantly decreases risk of ...

Recently there have been significant advances on several fronts in the ongoing war against cancer of the alimentary tract. Now, Japanese researchers report the development of another weapon: Linked ...

Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC). Radical nephroureterectomy with an ipsilateral bladder cuff is the ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...

Jelmyto shows long-term effectiveness in treating low-grade, upper tract urothelial carcinoma, with a high complete response rate in the OLYMPUS trial. The median duration of response for patients ...

"Patients with decreased eGFR at baseline are often those we are most interested in preserving their renal function with NSS. However, it was this cohort in whom we did not see any renal function ...

MSK’s comprehensive program for patients with upper tract urothelial carcinoma (UTUC) offers kidney-sparing treatment options whenever possible. “Traditionally, radical nephroueterectomy has been the ...

Mitomycin gel (Jelmyto), which received FDA approval in April 2020, addresses a need for a better way to treat low-grade UTUC, a malignancy that is challenging to manage. Tumor-ablative chemotherapy ...